170 related articles for article (PubMed ID: 25296628)
1. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions.
Maier S; Chung CH; Morse M; Platts-Mills T; Townes L; Mukhopadhyay P; Bhagavatheeswaran P; Racenberg J; Trifan OC
Cancer Med; 2015 Jan; 4(1):36-42. PubMed ID: 25296628
[TBL] [Abstract][Full Text] [Related]
2. Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test.
Dupont B; Mariotte D; Clarisse B; Galais MP; Bouhier-Leporrier K; Grellard JM; Le Mauff B; Reimund JM; Gervais R
Future Oncol; 2014 Nov; 10(14):2133-40. PubMed ID: 25471028
[TBL] [Abstract][Full Text] [Related]
3. A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils.
Iwamoto T; Okamoto A; Ishinaga H; Shimizu K; Gayle AA; Arai N; Takeuchi K; Okuda M
Cancer Med; 2016 Jun; 5(6):1004-12. PubMed ID: 26880699
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
[TBL] [Abstract][Full Text] [Related]
5. Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan.
Yamaguchi K; Watanabe T; Satoh T; Ishiguro M; Izawa M; Inoshiri S; Sugihara K; Sakata Y
Jpn J Clin Oncol; 2014 Jun; 44(6):541-6. PubMed ID: 24771864
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab-associated infusion reactions: pathology and management.
Patel DD; Goldberg RM
Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
Chung CH; Mirakhur B; Chan E; Le QT; Berlin J; Morse M; Murphy BA; Satinover SM; Hosen J; Mauro D; Slebos RJ; Zhou Q; Gold D; Hatley T; Hicklin DJ; Platts-Mills TA
N Engl J Med; 2008 Mar; 358(11):1109-17. PubMed ID: 18337601
[TBL] [Abstract][Full Text] [Related]
8. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
9. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences.
Schwartzberg LS; Stepanski EJ; Fortner BV; Houts AC
Support Care Cancer; 2008 Apr; 16(4):393-8. PubMed ID: 17909865
[TBL] [Abstract][Full Text] [Related]
10. Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.
Dupont B; Mariotte D; Dugué AE; Clarisse B; Grellard JM; Babin E; Chauffert B; Dakpé S; Moldovan C; Bouhier-Leporrier K; Reimund JM; Di Fiore F; Zanetta S; Mailliez A; Do P; Peytier A; Galais MP; Florescu C; Schott R; Le Mauff B; Gervais R
Br J Clin Pharmacol; 2017 Mar; 83(3):623-631. PubMed ID: 27662818
[TBL] [Abstract][Full Text] [Related]
11. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.
Keating K; Walko C; Stephenson B; O'Neil BH; Weiss J
J Oncol Pharm Pract; 2014 Dec; 20(6):409-16. PubMed ID: 24243920
[TBL] [Abstract][Full Text] [Related]
12. An infusion reaction to cetuximab.
Waxman ES
Oncology (Williston Park); 2011 Apr; 25(4 Suppl Nurse Ed):38-41. PubMed ID: 25391206
[No Abstract] [Full Text] [Related]
13. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
[TBL] [Abstract][Full Text] [Related]
14. Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: Outcomes and risk factors.
Caiado J; Brás R; Paulino M; Costa L; Castells M
Ann Allergy Asthma Immunol; 2020 Sep; 125(3):325-333.e1. PubMed ID: 32353405
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck.
Touma W; Koro SS; Ley J; Wildes TM; Michel L; Tao Y; Adkins D
Oral Oncol; 2014 Sep; 50(9):895-900. PubMed ID: 25037161
[TBL] [Abstract][Full Text] [Related]
16. A rare but severe pulmonary side effect of cetuximab in two patients.
Achermann Y; Frauenfelder T; Obrist S; Zaugg K; Corti N; Günthard HF
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22843749
[TBL] [Abstract][Full Text] [Related]
17. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Saif MW; Peccerillo J; Potter V
Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
[TBL] [Abstract][Full Text] [Related]
18. A patient on targeted therapy: cetuximab.
Vogel WH
Oncology (Williston Park); 2006 Sep; 20(10 Suppl Nurse Ed):25-7. PubMed ID: 18153976
[No Abstract] [Full Text] [Related]
19. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study.
Schwartzberg LS; Stepanski EJ; Walker MS; Mathias S; Houts AC; Fortner BV
Support Care Cancer; 2009 Jan; 17(1):91-8. PubMed ID: 18592276
[TBL] [Abstract][Full Text] [Related]
20. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
